FDA Review Of Children’s Cough/Cold OTCs Has Broader Implications
This article was originally published in The Tan Sheet
Executive Summary
FDA's review of children's over-the-counter cough/cold products will address the broader issue of whether extrapolating pediatric doses from adult dosing data is appropriate
You may also be interested in...
FDA Urged To Change OTC Monograph System, But Not In Midstream
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
FDA Urged To Change OTC Monograph System, But Not In Midstream
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
Risk/Benefit Value Tool Could Trim Guesswork From OTC Switch Attempts
The World Self Medication Industry and related trade groups created a value-tree framework with predefined major risk and benefit domains to help firms and regulators identify the opportunities and challenges a product or switch candidate poses.